       Document 0346
 DOCN  M9610346
 TI    Shortened survival in infants vertically infected with human
       immunodeficiency virus with elevated p24 antigenemia.
 DT    9601
 AU    Arlievsky NZ; Pollack H; Rigaud M; Kaul A; Krasinski K; Borkowsky W;
       Department of Pediatrics, New York University Medical Center, NY; 10016,
       USA.
 SO    J Pediatr. 1995 Oct;127(4):538-43. Unique Identifier : AIDSLINE
       MED/96006268
 AB    OBJECTIVE: To determine whether the amount of p24 antigenemia in the
       first 6 months of life is a predictor of survival in children infected
       vertically with human immunodeficiency virus type 1. METHODS: A
       retrospective study of vertically infected infants and children who were
       followed prospectively from early infancy and who had quantitation of
       plasma p24 antigen concentration in the first 6 months of life. Infants
       were first stratified by duration of survival as infants who died before
       2 years of age (short-term survivors) and infants who survived to 2
       years of age (intermediate-term survivors). The median p24 antigen
       concentration and the proportion of infants in each group with high
       concentrations of antigen were compared. Analyses with and excluding all
       p24 determinations made after the use of antiretroviral agents were
       compared Kaplan-Meier product limit analysis was used to compare
       survival in infants with low and high antigenemia during the first 6
       months of life. RESULTS: The median p24 antigen concentration in 15
       short-term survivors was 228 pg/ml, compared with 14 pg/ml in 26
       intermediate-term survivors (p < 0.05). The proportion of children with
       > 100 pg/ml of p24 was higher in short-term than in intermediate-term
       survivors (p = 0.01). Survival to 2 years of age in infants in whom all
       p24 antigen values during the first 6 months of life were 100 pg/ml or
       less was 91%, in comparison with 39% in infants with values greater than
       100 pg/ml (p = 0.0017). CONCLUSIONS: Elevated p24 antigenemia in the
       first 6 months of life is associated with shorter survival and may be a
       useful predictor of outcome.
 DE    Antigens, Viral/*BLOOD  Child  Child, Preschool  Comparative Study
       *Disease Transmission, Vertical  Human  HIV
       Seropositivity/BLOOD/MORTALITY/*TRANSMISSION  Infant  Infant, Newborn
       Prospective Studies  Retrospective Studies  Support, Non-U.S. Gov't
       Support, U.S. Gov't, P.H.S.  *Survival Analysis  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

